Matisse Pharmaceuticals B.V.

Matisse Pharmaceuticals B.V. is a startup based in the Netherlands.

Matisse Pharmaceuticals B.V. is a clinical-stage biopharmaceutical company developing therapies that neutralize extracellular cytotoxic histones; its lead program, isupartob sodium, is targeted at treating sepsis and septic shock. The company focuses on indications characterized by elevated extracellular histone levels and is progressing clinical development and regulatory interactions.